Background: In dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD), it is still debated whether white matter hyperintensities (WMH) on MRI reflect atherosclerotic cerebrovascular changes or Alzheimer's disease (AD)-related pathology such as cerebral amyloid angiopathy. To examine AD-related pathology in DLB and PDD, we compared the severity of WMH and medial temporal lobe atrophy among patients with DLB, PDD, non-demented PD (PDND), and AD.
Methods: We retrospectively studied sex- and age-matched outpatients with AD, DLB, PDD, and PDND, as well as subjects without central nervous system disorders as normal controls (n=50 each). All subjects underwent 1.5-T MRI examinations, and WMH detected by T2-weighted images or fluid-attenuated inversion recovery images were semiquantified according to the Fazekas method. Medial temporal lobe atrophy (MTA) was visually assessed by the MTA score.
Results: WMH were more prominent in AD, DLB, and PDD patients than in PDND patients and normal controls (NCs). DLB as well as AD showed more severe WMH than PDD. Visual assessment of medial temporal lobe atrophy showed that AD patients had the most severe atrophy, followed by DLB, PDD, and PDND patients, and NC subjects in that order. MTA scores showed significant correlations with WMH severity.
Conclusion: Our results indicated that DLB was more similar to AD than to PDD in terms of MRI findings, suggesting that WMH in DLB may reflect mainly AD-related pathology rather than atherosclerotic cerebrovascular changes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jns.2017.12.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The amplitude of resting-state electroencephalographic (rsEEG) rhythms is a promising neurophysiological biomarker to investigate the abnormalities of oscillatory neurophysiological thalamocortical mechanisms related to the general cortical arousal and vigilance in wakefulness in patients with dementia due to neurodegenerative diseases as Alzheimer's disease (ADD), Parkinson's disease (PDD) and Lewy Body disease (DLB). Here, we tested the hypothesis that the reactivity of posterior rsEEG alpha (about 8-12 Hz) rhythms during the transition from eyes-closed to -open condition may be lower in PDD patients than in DLB patients.
Methods: A Eurasian database provided clinical-demographic-rsEEG datasets in 35 ADD patients, 65 PDD patients, 30 DLB patients, and 25 matched cognitively unimpaired (Healthy) persons.
Biomarkers.
Alzheimers Dement
December 2024
USC Leonard Davis School of Gerontology, Los Angeles, CA, USA.
Background: Alzheimer's disease, along with other cognitive disorders such as frontotemporal dementia (FTD), dementia with Lewy body (DLB) Parkinson's disease dementia (PDD), and vascular cognitive impairment and dementia (VCD), comprise a range of conditions with similar cognitive symptoms but different pathophysiology. Currently, there is no biomarkers to distinguish them before death. The pathophysiological mechanisms differ significantly across these disorders, which implies a varied response to potential treatments.
View Article and Find Full Text PDFBackground: The Lewy body dementias are a class of neurodegenerative disease encompassing Parkinson's disease dementia (PDD) and Dementia with Lewy bodies (DLB). Despite similar clinical and neuropathological profiles, the principal differentiating feature is the sequence in which symptoms develop. A question still remains as to a biological basis of this difference and a potential explanation is epigenetic mechanisms, molecular processes which alter the way in which the underlying genetic sequence is expressed.
View Article and Find Full Text PDFBackground: The new anti-Aβ antibody drugs aducanumab and lecanemab (approved in the US, not yet in Europe) must be followed up closely and regularly long-term. Previous knowledge on progression of AD in routine clinical settings longterm is crucial when introducing new dementia medications. The Swedish national quality database on dementia/cognitive disorders, SveDem, where data on different dementia disorders at the time of the dementia diagnosis since 2007 and on mild cognitive impairment (MCI) since 2021 with annual follow-ups of MMSE scores can provide this unique information.
View Article and Find Full Text PDFBackground: Irsenontrine (e2027) is a potent and selective PDE9 inhibitor that increases cellular cGMP which is important for glutamatergic synaptic function. Irsenontrine was investigated to improve cognition in Lewy Body Dementia (LBD; DLB and PDD), and recent phase 2 study data suggests that irsenontrine could be more effective in DLB patients without amyloid copathology. Here, we evaluated differential change from baseline levels in proteins associated with cGMP pathway in DLB participants without amyloid co-pathology (DLB A-) compared to DLB participants with amyloid co-pathology (DLB A+).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!